Phase | Supervision period | |||
---|---|---|---|---|
Time-point | Baseline | Visit 1 | Visit 2 | Visit 3 |
Day | 0 | 6 ± 1 | 11 ± 1 | Follow-up |
Basic history collection | × | |||
Informed consent | × | |||
Demographics | × | |||
Enrollment based on the inclusion/exclusion criteria | × | |||
Coexisting diseases or symptoms | × | |||
Concomitant treatments | × | × | ||
Efficacy evaluation | ||||
Cough symptom score | × | × | × | × |
Cough VAS score | × | × | × | |
TCM syndrome score | × | × | × | |
CQLQ | × | × | ||
Safety evaluation | ||||
Vital signs | × | × | × | |
Blood routine and urine routine | × | × | ||
Liver function (ALT, AST, STB, ALP, γ-GT ) | × | × | ||
Renal function (Cr, BUN) | × | × | ||
ECG | × | × | ||
Adverse events | × | × | ||
Screening tests | ||||
CR | × | |||
BPT | × | |||
UPT (women of childbearing age) | × | |||
Other steps | ||||
Randomization allocation | × | |||
Drug distribution | × | |||
Remaining drug count | × | |||
Patient record card distribution/recycling | × | × |